BioPharma Dive

Recent stories from BioPharma Dive.

BioPharma Dive Gwendolyn Wu

BIO unveils plan for US to remain biotech’s ‘global leader’

A seven-part proposal from the prominent lobbyist lays out a series of initiatives to accelerate drug development in the U.S. and counter China’s fast rise.

Read at BioPharma Dive

BioPharma Dive Jacob Bell

Bayer wins FDA nod for a new kind of blood thinner

Sunharbo’s U.S. approval is the first for a “Factor XIa” inhibitor, an anticipated class of medicines seen as a possible step forward in stroke prevention.

Read at BioPharma Dive

BioPharma Dive Delilah Alvarado

Vir hepatitis D drug succeeds in first pivotal study

A program that’s survived Vir’s pivot away from infectious disease research hit all of its study objectives and appeared more potent than a rival drug also in late-stage development.

Read at BioPharma Dive

BioPharma Dive Jacob Bell

Argenx to buy peptide platform in potentially billion-dollar deal

For $550 million up front, Argenx will take control of Unnatural Products’ “macrocyclic peptide” technology and direct it to develop oral, durable medicines for serious immune-mediated diseases.

Read at BioPharma Dive

BioPharma Dive Sy Mukherjee

Ramaswamy’s biotech baggage haunted his political run

A pivotal Alzheimer’s trial tied to Vivek Ramaswamy’s political rise is a tale of failed endpoints.

Read at BioPharma Dive

BioPharma Dive Dennis Kirkpatrick, DPR Construction

Making the ‘impossible’ executable in life sciences construction

Why early technical expertise matters when complex life sciences projects challenge convention.

Read at BioPharma Dive

BioPharma Dive

Translating Phase II success into Phase III readiness takes more than scale

The move from Phase II to Phase III is often treated as a clinical milestone, when it is actually a development-wide transition.

Read at BioPharma Dive